Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Short term Debt (2018 - 2024)

Historic Short term Debt for Neurocrine Biosciences (NBIX) over the last 5 years, with Q1 2024 value amounting to $122.8 million.

  • Neurocrine Biosciences' Short term Debt changed N/A to $122.8 million in Q1 2024 from the same period last year, while for Mar 2024 it was $122.8 million, marking a year-over-year change of. This contributed to the annual value of $170.1 million for FY2023, which is N/A changed from last year.
  • Per Neurocrine Biosciences' latest filing, its Short term Debt stood at $122.8 million for Q1 2024.
  • Over the past 5 years, Neurocrine Biosciences' Short term Debt peaked at $425.0 million during Q3 2020, and registered a low of $122.8 million during Q1 2024.
  • For the 3-year period, Neurocrine Biosciences' Short term Debt averaged around $246.2 million, with its median value being $170.0 million (2023).